VitaNova Life Sciences annual return on equity
2024
2025
2026
VitaNova Life Sciences Return on Equity (ROE) Growth & History (VNOV)
VitaNova Life Sciences's return on equity was −1.88% for fiscal 2026.
View full VitaNova Life Sciences company overviewVitaNova Life Sciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-30 | −1.88% | −59.28 pp |
| 2025 | 2025-04-30 | 57.39% | +29.13 pp |
| 2024 | 2024-04-30 | 28.27% | — |
VitaNova Life Sciences quarterly return on equity
Q3.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2026 | 2026-04-30 | 0.90% | −52.16 pp |
| Q3 2026 | 2026-01-31 | −2.36% | −9.17 pp |
| Q2 2026 | 2025-10-31 | 1.90% | −1.30 pp |
| Q1 2026 | 2025-07-31 | −2.46% | +2.91 pp |
| Q4 2025 | 2025-04-30 | 53.05% | +35.62 pp |
| Q3 2025 | 2025-01-31 | 6.81% | +5.28 pp |
| Q2 2025 | 2024-10-31 | 3.21% | — |
| Q1 2025 | 2024-07-31 | −5.37% | — |
| Q4 2024 | 2024-04-30 | 17.43% | — |
| Q3 2024 | 2024-01-31 | 1.53% | — |
| Q2 2019 | 2018-10-31 | −303.64% | −324.50 pp |
| Q1 2019 | 2018-07-31 | −46.22% | — |
| Q4 2018 | 2018-04-30 | −9.48% | — |
| Q3 2018 · Jan 31 | 2018-01-31 | −24.18% | — |
| Q3 2018 · Oct 31 | 2017-10-31 | 20.86% | — |
VitaNova Life Sciences return on equity trends
Between the periods ended 2024-04-30 and 2026-04-30, VitaNova Life Sciences's return on equity decreased from 28.27% to −1.88%, a change of −30.15 percentage points. The latest reported quarter, Q4 2026, shows 0.90%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review VitaNova Life Sciences source filings ↗